Phenominer Database Results (57 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Clinical Measurement Notes Record ID Study ID
WKY afferent arteriolar plasma protein concentration controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 8 5.5 g/dl 0.1 0.28 plasma total protein analysis renal afferent arteriole 0.0 PA IV 50mg/kg ca 100571 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 8 305.0 g 6.0 16.97 body weighing method 0.0 PA IV 50mg/kg 100432 2479
WKY systolic blood pressure controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 9 96.0 mmHg 2.0 6.0 tail cuff plethysmography 0.0 PA IV 50mg/kg 490 days 100453 2479
WKY glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 0.38 ml/min 0.08 0.18 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100456 2479
WKY mean proximal tubular hydraulic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 16.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg pt 100541 2479
WKY efferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 24.0 x 10E10 dyne x s/cm5 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg pe 100546 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.28 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100480 2479
WKY plasma sodium level controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 9 146.0 mmol/l 3.0 9.0 automated plasma analysis 0.0 PA IV 50mg/kg 490 days 100489 2479
WKY plasma potassium level controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 8 4.7 mmol/l 0.3 0.85 automated plasma analysis 0.0 PA IV 50mg/kg 100495 2479
WKY urine sodium excretion rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 8 0.3 mEq/d 0.04 0.12 urine sodium analysis 0.0 PA IV 50mg/kg 100504 2479
WKY urine sodium excretion rate controlled enalapril content drinking water (50 mg/kg) (for 497 days) then puromycin aminonucleoside (50 mg/l) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 9 0.69 mEq/d 0.24 0.73 urine sodium analysis 0.0 PA IV 50mg/kg 490 days 100507 2479
WKY serum albumin level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male  days 10 1.4 g/dl 0.1 0.32 radial immunodiffusion assay 0.0 PA IV 50mg/kg 23 days 100417 2479
WKY afferent arteriolar plasma flow rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 8 244.0 nl/min 21.0 59.4 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg afferent arteriolar plasma flow rate 100531 2479
WKY glomerular capillary hydraulic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 46.0 mmHg 2.0 5.66 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg pgc 100536 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 9 5.45 ml/min 0.19 0.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100471 2479
WKY plasma sodium level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 5 138.0 mmol/l 2.0 4.47 automated plasma analysis 0.0 PA IV 50mg/kg 23 days 100483 2479
WKY plasma potassium level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 5 5.8 mmol/l 0.4 0.89 automated plasma analysis 0.0 PA IV 50mg/kg 23 days 100492 2479
WKY urine sodium excretion rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 5 0.04 mEq/d 0.01 0.03 urine sodium analysis 0.0 PA IV 50mg/kg 15 days 100501 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 12 312.0 g 4.0 13.86 body weighing method 0.0 PA IV 50mg/kg 100396 2479
WKY efferent colloid osmotic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 29.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg pie 100586 2479
WKY glomerular capillary ultrafiltration coefficient controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 0.11 nl/(s x mmHg) 0.03 0.07 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg kf 100591 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 9 395.0 g 7.0 21.0 body weighing method 0.0 PA IV 50mg/kg 490 days 100435 2479
WKY hematocrit controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 5 35.0 % 1.0 2.24 hematocrit analysis 0.0 PA IV 50mg/kg 23 days 100438 2479
WKY glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 1.25 ml/min 0.09 0.25 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100459 2479
WKY plasma renin activity level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male  days 10 100.3 ng/ml/h 18.6 58.82 radioimmunoassay 0.0 PA IV 50mg/kg 23 days 100423 2479
WKY glomerular transcapillary hydraulic pressure gradient controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 31.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg dp 100551 2479
WKY total arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 1.53 x 10E10 dyne x s/cm5 0.12 0.34 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg rt 100566 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 0.28 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100477 2479
WKY urine potassium excretion rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 5 0.29 mEq/d 0.09 0.19 urine potassium analysis 0.0 PA IV 50mg/kg 15 days 100510 2479
WKY urine potassium excretion rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 8 0.49 mEq/d 0.04 0.12 urine potassium analysis 0.0 PA IV 50mg/kg 100513 2479
WKY urine potassium excretion rate controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 9 2.16 mEq/d 0.27 0.82 urine potassium analysis 0.0 PA IV 50mg/kg 490 days 100516 2479
WKY serum total cholesterol level controlled enalapril content drinking water (50 mg/l) (for 26 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male  days 10 360.0 mg/dl 45.0 142.3 serum total cholesterol measurement test 0.0 PA IV 50mg/kg 19 days 100405 2479
WKY serum total cholesterol level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male  days 12 104.0 mg/dl 10.0 34.64 serum total cholesterol measurement test 0.0 PA IV 50mg/kg 100408 2479
WKY serum triglyceride level controlled enalapril content drinking water (50 mg/l) (for 26 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male  days 10 240.0 mg/dl 19.0 60.08 serum triglyceride analysis 0.0 PA IV 50mg/kg 19 days 100411 2479
WKY afferent colloid osmotic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 18.0 mmHg 0.3 0.85 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg pia 100581 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 10 241.0 g 5.0 15.81 body weighing method 0.0 PA IV 50mg/kg 15 days 100393 2479
WKY hematocrit controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 8 43.0 % 1.0 2.83 hematocrit analysis 0.0 PA IV 50mg/kg 100441 2479
WKY systolic blood pressure controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 8 100.0 mmHg 1.0 2.83 tail cuff plethysmography 0.0 PA IV 50mg/kg 100450 2479
WKY glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 1.43 ml/min 0.09 0.27 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100462 2479
WKY single nephron glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 61.0 nl/min 3.0 8.49 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100521 2479
WKY afferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 1.04 x 10E10 dyne x s/cm5 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg ra 100556 2479
WKY efferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 0.5 x 10E10 dyne x s/cm5 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg re 100561 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 8 4.15 ml/min 0.32 0.91 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100468 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 0.09 null 0.01 0.02 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100474 2479
WKY plasma potassium level controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 9 4.7 mmol/l 0.3 0.9 automated plasma analysis 0.0 PA IV 50mg/kg 490 days 100498 2479
WKY urine total protein excretion rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male  days 10 115.0 mg/d 10.0 31.62 metabolic cage urine volume measurement method 0.0 PA IV 50mg/kg 15 days 100399 2479
WKY urine total protein excretion rate controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male  days 12 10.0 mg/d 1.0 3.46 metabolic cage urine volume measurement method 0.0 PA IV 50mg/kg 100402 2479
WKY serum triglyceride level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male  days 12 72.0 mg/dl 9.0 31.18 serum triglyceride analysis 0.0 PA IV 50mg/kg 100414 2479
WKY efferent arteriolar plasma protein concentration controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 8 7.5 g/dl 0.3 0.85 plasma total protein analysis renal efferent arteriole 0.0 PA IV 50mg/kg ce 100576 2479
WKY plasma renin activity level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male  days 12 206.8 ng/ml/h 20.7 71.71 radioimmunoassay 0.0 PA IV 50mg/kg 100426 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 5 245.0 g 12.0 26.83 body weighing method 0.0 PA IV 50mg/kg 15 days 100429 2479
WKY systolic blood pressure controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 5 95.0 mmHg 9.0 20.12 tail cuff plethysmography 0.0 PA IV 50mg/kg 15 days 100447 2479
WKY hematocrit controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 9 42.0 % 1.0 3.0 hematocrit analysis 0.0 PA IV 50mg/kg 490 days 100444 2479
WKY serum albumin level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male  days 12 3.6 g/dl 0.1 0.35 radial immunodiffusion assay 0.0 PA IV 50mg/kg 100420 2479
WKY single nephron filtration fraction controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 0.26 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100526 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 5 3.95 ml/min 0.7 1.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100465 2479
WKY plasma sodium level controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 8 148.0 mmol/l 2.0 5.66 automated plasma analysis 0.0 PA IV 50mg/kg 100486 2479